Background. The association between proton pump inhibitors (PPIs) and nontyphoid salmonellosis (NTS) continues to be debated. The current study was designed to determine the association between use of oral PPIs and the diagnosis of NTS.
Nontyphoid salmonellosis (NTS) is one of the most common foodborne diseases worldwide, affecting millions of persons each year [1, 2] . Usually acquired by consumption of contaminated food, especially eggs and poultry products, NTS may cause gastroenteritis, bacteremia, and focal infections [3] . Predisposing host factors include gastric hypoacidity [1] , diabetes [3, 4] , autoimmune diseases [1, 4] , cancer [5] , hepatic cirrhosis [3] , gallstones [1] , previous gastrointestinal surgery [6] , AIDS [7, 8] , and prior use of antimicrobial agents [3, 7, 8] . Proton pump inhibitors (PPIs) have also been associated with NTS [9] [10] [11] . This association is thought to be due to disruption of the natural gut microbial ecology [12] caused by inhibition of gastric acid secretion, mucosal permeability [13] , and neutrophil bactericidal activity [14] . Most studies have shown an association between PPI use and susceptibility to NTS but failed to consider the confounding effects of host factors that enhance susceptibility to NTS [9] [10] [11] . A recent study, which controlled for individual confounding factors by using the patients as their own control over a 12-month period, found no association between PPIs use and NTS, suggesting that predisposing factors other than PPIs may contribute to the increased rate of NTS [15] .
Because of the conflicting results in the literature, problems of selection bias [16] , and differences in the intervals of time between the use of a PPI and onset of NTS we believed that a large, community-based study was needed to adjust for the effect of predisposing host factors and to determine the critical interval between use of a PPI and the onset of NTS. To accomplish this we conducted a nested case-control study, matching for demographic and predisposing host factors for NTS. The Taiwan National Health Insurance Research Database (NHIRD) 2000-2010 was used to identify a large number of case patients and controls during an 11-year period.
METHODS

Data Sources
Taiwan National Health Insurance was established in 1995. It includes 98% of the population because of mandatory, universal enrollment. All of diagnoses are in accord with the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). All procedures and medications of the patients enrolled in the insurance system are recorded and stored in the NHIRD maintained by the National Health Research Institute. Two databases derived from the original NHIRD were used in this study. The first contains all beneficiaries with all infectionrelated ICD-9-CM codes during 1996-2010 from the original NHIRD (ID Database). The other is the Longitudinal Health Insurance Database data set containing complete data for 1 000 000 randomly sampled beneficiaries during 1996-2010 from the original NHIRD. The data set used in this study consists of deidentified secondary data released to the public for research purposes. This study was approved by the institutional review board of the National Health Research Institute.
Settings and Participants
This hospitalized population-based nested case-control study consisted of patients with a diagnosis of NTS and matched controls during 2000-2010 in Taiwan. We used the database from January 1996 to December 1999 to ensure that all individuals were available for at least a 4-year follow-up before enrollment to confirm comorbid conditions [17] and matching. Case patients were selected from the ID Database if they had a diagnosis of NTS (ICD-9-CM 003.XX) and the coding date was deemed the index date. A pool of potential eligible controls with the same follow-up period as the case patient but without a previous ICD-9 code for NTS was extracted from the Longitudinal Health Insurance Database. From these eligible controls, 4 were selected randomly and matched to a case patient by age (±1 year), month and year of cohort entry, Charlson comorbidity index score [18] , and predisposing factors for NTS, which included autoimmune diseases [1, 4] , AIDS [7, 8] , diabetes [3, 4] , gallstones [1] , kidney transplantation [19] , hepatic cirrhosis [3] , previous gastrointestinal surgery [6] , and solid tumors and hematologic or metastatic cancer [5, 8] . Medications that have been shown to be associated with NTS [7] [8] [9] 15] were included in the analysis; these included antibiotics, corticosteroids, H2-receptor antagonists, and nonsteroidal anti-inflammatory drugs (NSAIDs).
Exposure Assessment
We identified all oral PPIs prescribed in the year before the index date; PPIs included omeprazole, pantoprazole, lansoprazole, rabeprazole, and esomeprazole. We classified PPI use as current, recent, or past use, based on the timing of the prescription termination date (date of dispensation plus number of days of supply) and the NTS index date [20] . Current users were defined as those in whom NTS was diagnosed during the PPI prescription period. Recent and past users were defined as those in whom NTS was diagnosed 1-30 or 31-365 days after the prescription termination date, respectively.
Statistical Analysis
The demographic characteristics of the patients and controls were compared by means of χ for the fit of our model. The Microsoft SQL Server 2008 R2 (Microsoft) was used for data linkage, processing, and sampling. All analyses were performed using SAS software, version 9.2 (SAS Institute), with 2-sided tests of significance at P < .05.
RESULTS
We identified 14 736 patients with NTS and 58 944 corresponding controls during the 11-year study period. The characteristics of the case patients and controls are shown in Table 1 . Patients with NTS were more likely than controls to have had hypertension or coronary artery disease and to have received concurrent medications, including antibiotics, H2-receptor antagonists, steroids, and NSAIDs. Table 2 shows crude and adjusted ORs for PPI use in case patients with a diagnosis of NTS, compared to controls, after adjustment for all variables with P values <.05 in Table 1 . The P value of McFadden's adjusted R 2 for the fit of our model was .243. Both crude and adjusted ORs for PPI usage within 30 days before the index date were significantly greater (P < .001) in case patients than in controls. There was a relationship between the time of PPI use and the onset of NTS. The adjusted OR for current PPI use was 5.39 (P < .001). This dropped to 4.20 (P < .001) for PPIs discontinued within 7 days before the index date and to 1.90 (P < .001) for PPIs discontinued 8-30 days before the index date. The median time from termination of the PPI prescription to diagnosis of NTS was 9 days for recent users (interquartile range, 3-18 days) and 155 days (84-244 days) for past PPI users. There was no significant difference in past PPI use (>30 days) between case patients and controls (P = .86).
Although the recent or current use of H2-receptor antagonists, antibiotics, steroids, and NSAIDs was also associated with NTS (all P < .001; Table 2 ), the linkage between PPI use and NTS remained significant in the subgroup without use of these medications (adjusted OR, 2.34; 95% confidence interval, 2.11-2.59; P < .001). Similarly, we found that the odds of having current or recent, but not past use of PPI in patients with a diagnosis of campylobacteriosis were significantly higher than in those without campylobacteriosis (Supplementary Table 1 ). We did not find a similar association for shigellosis (Supplementary Table 2) .
DISCUSSION
This nested case-control study provides further evidence that PPI use is associated with an increased risk of NTS after matching for well-known predisposing factors. The risk of acquisition of NTS was highest among current users and waned with time after use of PPIs. Proton pump inhibitors reduce acid secretion by selective inhibition of gastric hydrogen-potassium adenosine triphosphatase. They are currently the major drugs for treatment of gastroesophageal reflux and peptic ulcer diseases [21] . Thus, the potential side effects of PPIs are of imperative concern because of their widespread use. Many studies have shown an association between PPIs use and enteric infections [9] [10] [11] 22] . The adjusted relative risk of the associations ranged from 4.2 to 8.3 in case-control studies [23] . The association between NTS and H2-receptor antagonists found in our study and others [9, 11] also supports the notion that acid suppression is associated with increased risk of gastrointestinal infections.
The association between PPI use and NTS was reevaluated in a population-based cohort study comparing the incidence rates of NTS in PPI users and nonusers [15] . After adjusting for unmeasured confounding and eliminating the effect of time intervals, the authors concluded that the risk is probably attributable to predisposing factors among PPI users, rather than to the PPIs themselves; the problem with the study, however, was that it compared the incidence of NTS 12 months before and after the use of PPIs, and this design probably diluted the immediate effect of PPIs. It has been shown elsewhere that the effect of PPIs on increasing susceptibility to NTS appeared within 3 months after PPI treatment ended [10] . Our study, like previous ones [9] [10] [11] 22] , still demonstrated the significant association between the risk of NTS and PPI use. In addition, if predisposing factors were the main culprits, the risk for NTS should not have decreased with time after discontinuation of PPIs.
The strengths of the current study include the large numbers of case patients and controls representative of the entire country of Taiwan, the ability to carefully match for well-known predisposing factors, and the ability to define the interval between receipt of a PPI and occurrence of NTS and the long-term follow-up period provided by our databases. The study also had several limitations. It was confined to inpatients, in whom microbiologic examination could be conducted more thoroughly than outpatients. Some risk factors for NTS, such as traveling abroad and ingestion of products containing raw eggs, were not adjusted for. There may have been surveillance bias, because the diagnosis of NTS might have been influenced by a history of prior PPI use. The low incidence rate of NTS did not allow a prospective design, and the study design may not able to demonstrate causality. PPIs could be prescribed for symptoms that turned out to be due to NTS. There might be bias with the use of PPIs for prophylaxis of gastrointestinal bleeding, because gastrointestinal bleeding and NTS share several risk factors (eg, steroid use); this was not an issue in our study, however, because the strict reimbursement policy in Taiwan requires that the use of H2 blockers rather than oral PPIs for prophylaxis of gastrointestinal bleeding.
In conclusion, we found a temporal association between the use of PPIs and increased susceptibility to NTS after matching for predisposing factors. Healthcare providers should consider the increased risk of NTS even within 30 days after the PPI being discontinued.
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